Liu Chong, Liu Yong, He Jing, Mu Rong, Di Yanbo, Shen Na, Liu Xuan, Gao Xiao, Wang Jinhui, Chen Tie, Fang Tao, Li Huanming, Tian Fengshi
Department of Anaesthesiology, Tianjin 4th Centre Hospital, The Fourth Central Hospital Affiliated to Nankai University, The Fourth Center Clinical College of Tianjin Medical University, Tianjin, China.
Central Laboratory, Tianjin 4th Centre Hospital, The Fourth Central Hospital Affiliated to Nankai University, The Fourth Center Clinical College of Tianjin Medical University, Tianjin, China.
Front Pharmacol. 2019 Jul 24;10:789. doi: 10.3389/fphar.2019.00789. eCollection 2019.
Liraglutide (Lir) is a glucagon-like peptide-1 receptor agonist that lowers blood sugar and reduces myocardial infarct size by improving endothelial cell function. However, its mechanism has not yet been clarified. Unfolded protein response (UPR) plays an important role in the pathogenesis of myocardial ischemia-reperfusion injury. It determines the survival of cells. Endoplasmic reticulum position protein homologue 2 (CNPY2) is a novel initiator of UPR that also participates in angiogenesis. To this extent, the current study further explored whether Lir regulates angiogenesis through CNPY2. In our article, a hypoxia/reoxygenation (H/R) injury model of human umbilical vein endothelial cells (HUVECs) was established and the effect of Lir on HUVECs was first evaluated by the Cell Counting Kit-8. Endothelial tube formation was used to analyze the ability of Lir to induce angiogenesis. Subsequently, the effect of Lir on the concentrations of hypoxia-inducible factor 1α (HIF1α), vascular endothelial growth factor (VEGF), and CNPY2 was detected by enzyme-linked immunosorbent assay. To assess whether Lir regulates angiogenesis through the CNPY2-initiated UPR pathway, the expression of UPR-related pathway proteins (CNPY2, GRP78, PERK, and ATF4) and angiogenic proteins (HIF1α and VEGF) was detected by reverse transcription-polymerase chain reaction and Western blot. The results confirmed that Lir significantly increased the expression of HIF1α and VEGF as well as the expression of CNPY2-PERK pathway proteins in HUVECs after H/R injury. To further validate the experimental results, we introduced the PERK inhibitor GSK2606414. GSK2606414 was able to significantly decrease both the mRNA and protein expression of ATF4, HIF1α, and VEGF in vascular endothelial cells after H/R injury. The effect of Lir was also inhibited using GSK2606414. Therefore, our study suggested that the CNPY2-PERK pathway was involved in the mechanism of VEGF expression after H/R injury in HUVECs. Lir increased the expression of VEGF through the CNPY2-PERK pathway, which may promote endothelial cell angiogenesis and protect HUVEC from H/R damage.
利拉鲁肽(Lir)是一种胰高血糖素样肽-1受体激动剂,可降低血糖并通过改善内皮细胞功能减小心肌梗死面积。然而,其机制尚未阐明。未折叠蛋白反应(UPR)在心肌缺血再灌注损伤的发病机制中起重要作用。它决定细胞的存活。内质网定位蛋白同源物2(CNPY2)是UPR的一种新型启动因子,也参与血管生成。在此范围内,本研究进一步探讨了Lir是否通过CNPY2调节血管生成。在我们的文章中,建立了人脐静脉内皮细胞(HUVECs)的缺氧/复氧(H/R)损伤模型,并首先通过细胞计数试剂盒-8评估Lir对HUVECs的影响。采用内皮管形成实验分析Lir诱导血管生成的能力。随后,通过酶联免疫吸附测定法检测Lir对缺氧诱导因子1α(HIF1α)、血管内皮生长因子(VEGF)和CNPY2浓度的影响。为了评估Lir是否通过CNPY2启动的UPR途径调节血管生成,通过逆转录-聚合酶链反应和蛋白质印迹法检测UPR相关途径蛋白(CNPY2、GRP78、PERK和ATF4)和血管生成蛋白(HIF1α和VEGF)的表达。结果证实,Lir显著增加了H/R损伤后HUVECs中HIF1α和VEGF的表达以及CNPY2-PERK途径蛋白的表达。为了进一步验证实验结果,我们引入了PERK抑制剂GSK2606414。GSK2606414能够显著降低H/R损伤后血管内皮细胞中ATF4、HIF1α和VEGF的mRNA和蛋白表达。使用GSK2606414也抑制了Lir的作用。因此,我们的研究表明,CNPY2-PERK途径参与了HUVECs在H/R损伤后VEGF表达的机制。Lir通过CNPY2-PERK途径增加VEGF的表达,这可能促进内皮细胞血管生成并保护HUVECs免受H/R损伤。